Chembio Diagnostics (NASDAQ:CEMI) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Chembio Diagnostics (NASDAQ:CEMIGet Rating) announced its quarterly earnings data on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.08), MarketWatch Earnings reports. Chembio Diagnostics had a negative net margin of 70.90% and a negative return on equity of 89.24%. During the same quarter in the previous year, the company posted ($0.22) EPS.

CEMI stock traded down $0.11 on Friday, hitting $0.56. 270,626 shares of the company were exchanged, compared to its average volume of 194,877. Chembio Diagnostics has a twelve month low of $0.53 and a twelve month high of $7.34. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.59 and a quick ratio of 2.74. The business’s fifty day moving average is $0.75 and its two-hundred day moving average is $1.25. The stock has a market capitalization of $16.86 million, a price-to-earnings ratio of -0.38 and a beta of 1.73.

Several equities analysts recently issued reports on CEMI shares. Zacks Investment Research downgraded shares of Chembio Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 9th. Colliers Securities reissued a “neutral” rating on shares of Chembio Diagnostics in a research note on Tuesday, March 22nd. Finally, StockNews.com assumed coverage on shares of Chembio Diagnostics in a research note on Thursday. They set a “sell” rating on the stock.

A number of hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in Chembio Diagnostics by 2,264.1% during the fourth quarter. JPMorgan Chase & Co. now owns 33,452 shares of the company’s stock worth $38,000 after purchasing an additional 32,037 shares during the last quarter. Geode Capital Management LLC increased its position in Chembio Diagnostics by 40.4% during the third quarter. Geode Capital Management LLC now owns 203,070 shares of the company’s stock worth $507,000 after purchasing an additional 58,448 shares during the last quarter. Morgan Stanley increased its position in shares of Chembio Diagnostics by 235.8% in the third quarter. Morgan Stanley now owns 122,123 shares of the company’s stock worth $305,000 after acquiring an additional 85,756 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Chembio Diagnostics in the fourth quarter worth $105,000. Finally, Virtu Financial LLC increased its position in shares of Chembio Diagnostics by 506.7% in the fourth quarter. Virtu Financial LLC now owns 119,238 shares of the company’s stock worth $136,000 after acquiring an additional 99,585 shares in the last quarter. 13.27% of the stock is owned by hedge funds and other institutional investors.

About Chembio Diagnostics (Get Rating)

Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases.

Recommended Stories

Earnings History for Chembio Diagnostics (NASDAQ:CEMI)

Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.